These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23060621)

  • 41. Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma.
    Quaranta L; Miglior S; Floriani I; Pizzolante T; Konstas AG
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4226-31. PubMed ID: 18502991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.
    Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Twenty-four-hour intraocular pressure measurement in glaucoma.
    Myers JS; Fudemberg SJ
    Clin Exp Ophthalmol; 2015 Dec; 43(9):782-3. PubMed ID: 26638201
    [No Abstract]   [Full Text] [Related]  

  • 44. Risk factors for subject withdrawals in clinical trials evaluating glaucoma medications.
    Stewart WC; Demos CM; Turner MK; Stewart JA
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):1007-12. PubMed ID: 20213475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarkers and surrogate endpoints in glaucoma clinical trials.
    Medeiros FA
    Br J Ophthalmol; 2015 May; 99(5):599-603. PubMed ID: 25034049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging drugs for the treatment of glaucoma: a review of phase II & III trials.
    Kaplan TM; Sit AJ
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):321-331. PubMed ID: 35924872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The treatment of normal-tension glaucoma.
    Caprioli J
    Am J Ophthalmol; 1998 Oct; 126(4):578-81. PubMed ID: 9780103
    [No Abstract]   [Full Text] [Related]  

  • 48. Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma.
    Fenwick EK; Man RE; Aung T; Ramulu P; Lamoureux EL
    Prog Retin Eye Res; 2020 May; 76():100801. PubMed ID: 31676347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-Organ Bias in Published Randomized Controlled Trials of Glaucoma.
    Esen F; Köstek M; Emekli AS; Eraslan M
    J Glaucoma; 2016 Jun; 25(6):520-2. PubMed ID: 26796312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intraocular pressure and glaucoma.
    Mikelberg FS
    Can J Ophthalmol; 1993 Oct; 28(6):251-3. PubMed ID: 8299047
    [No Abstract]   [Full Text] [Related]  

  • 51. [Innovative glaucoma therapy].
    Flammer J
    Ophthalmologe; 2001 Oct; 98(10):923-4. PubMed ID: 11699311
    [No Abstract]   [Full Text] [Related]  

  • 52. Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development.
    Storgaard L; Tran TL; Freiberg JC; Hauser AS; Kolko M
    Front Med (Lausanne); 2021; 8():733080. PubMed ID: 34589504
    [No Abstract]   [Full Text] [Related]  

  • 53. Letter to the Editor relating to Graefe's Arch Clin Exp Ophthalmol. 2020 June. "Medical management of pediatric glaucoma: lessons learned from randomized clinical trials".
    Quaranta L; Riva I; Micheletti E; Katsanos A
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2047-2048. PubMed ID: 32696322
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to "Letter to the Editor relating to Graefe's Arch Clin Exp Ophthalmol. 2020 June. 'Medical management of pediatric glaucoma: lessons learned from randomized clinical trials'".
    Sacchi M; Lizzio RAU; Villani E; Monsellato G; Lucentini S; Cremonesi E; Luccarelli S; Serafino M; Nucci P
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2049-2050. PubMed ID: 32734469
    [No Abstract]   [Full Text] [Related]  

  • 55. Minimizing efficacy differences between phase II and III RCTs.
    Strand V
    Nat Rev Rheumatol; 2020 Jul; 16(7):359-360. PubMed ID: 32504076
    [No Abstract]   [Full Text] [Related]  

  • 56. [Not Available].
    Bamberger M; Moore N; Lechat P;
    Therapie; 2011; 66(4):327-30. PubMed ID: 27392459
    [No Abstract]   [Full Text] [Related]  

  • 57. Time to abandon placebo control in pivotal phase III trials?
    Geddes JR; Cipriani A
    World Psychiatry; 2015 Oct; 14(3):306-7. PubMed ID: 26407783
    [No Abstract]   [Full Text] [Related]  

  • 58. Single-versus double-masking in glaucoma clinical trials.
    DeMill DL; Wirostko BM; Nelson LA; Stewart JA; Stewart WC
    Perspect Clin Res; 2016; 7(3):147-8. PubMed ID: 27453833
    [No Abstract]   [Full Text] [Related]  

  • 59. [Not Available].
    Paintaud G; Diviné M; Lechat P;
    Therapie; 2012; 67(4):319-27. PubMed ID: 27393609
    [No Abstract]   [Full Text] [Related]  

  • 60. Alternative placebo treatment arms in trials: Implications may vary with differential results.
    Mahajan R
    Int J Appl Basic Med Res; 2015; 5(3):159-60. PubMed ID: 26539361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.